Next Investors logo grey

Nanosonics delivers maiden full-year profit on back of strong sales growth

Published 18-AUG-2016 13:35 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Provider of decontamination products to the healthcare industry, Nanosonics (ASX:NAN), announced on Wednesday that it had recorded a maiden full-year profit of $122,000. The business has gained significant momentum over the last six months, evidenced by the fact that the group generated a profit of $3.4 million in the second half of fiscal 2016.

Consequently, the company appears to now be squarely on the front foot with a portfolio of decontamination products and established proprietary technology placing it well to grow sales in global markets where it is already represented, as well as entering new regions.

Next Investors Image

Scott Power from Morgans CIMB was impressed with the result and following a meeting with management yesterday he made upward adjustments to projected contributions from the company’s higher margin consumables business, as well as increasing the anticipated installed base from 8700 units to 10,000 units.

This would imply growth of 25% in fiscal 2017 and 20% thereafter. While this would result in a near-term increase in the group’s cost base, the result relative to his current forecasts for fiscal 2017 is earnings neutral and 4% accretive in 2018.

Power is forecasting Nanosonics to generate a profit of $7 million in fiscal 2017, increasing to $18.5 million in 2018, representing earnings per share of 6 cents. He sees exponential growth occurring thereafter with earnings per share doubling again in fiscal 2019.

While there appeared to be an anticipation of an upcoming strong result as Nanosonic’s shares increased approximately 20% from circa $2.40 in mid-July to yesterday’s closing price of $2.80, Power sees scope for further share price upside, and following the result he increased his price target from $2.73 to $3.04.

It should be noted that broker recommendations, forecasts and price targets are not necessarily an indication of the company’s future performance and as such should not form the basis of an investment decision. Furthermore, historical share price performance is not an indicator of a company’s future trading patterns and should not form the basis of an investment decision.

Nanosonics chief executive, Michael Kavanagh, pointed to several developments occurring in the health industry which suggest there will be increasing demand for its medical instrument decontaminating products.

He is of the view that adoption of the group’s products has strengthened with the publication of a number of papers including evidence demonstrating that the group’s Trophon technology is the only proven technology to kill human papillomavirus (HPV).

Kavanagh also noted that new guidance had been published in Scotland requiring high-level disinfection for all semi-critical ultrasound examinations with expectations new guidance will be published in the UK in the first quarter of fiscal 2017.

It has been historically the case that industry developments such as these provide share price momentum for the group. The other development to monitor is the company’s entry into new markets with management confirming yesterday that it was in advanced negotiations with a number of countries in the Middle East.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.